TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris - PubMed
6 hours ago
- #TYK2 Inhibition
- #Deucravacitinib
- #Lichen Planopilaris
- Deucravacitinib, an oral TYK2 inhibitor, was studied in a clinical trial for Lichen Planopilaris (LPP), a scarring alopecia.
- After 24 weeks, patients showed significant improvements in clinical scores: PGA, LPPAI, and Skindex-16.
- Bulk RNA sequencing revealed upregulation of type I interferon pathways pre-treatment, which were downregulated post-treatment.
- Single-cell RNA-seq identified enriched CD8+GZMK+ T cells in LPP, with reduced T-cell receptor and antiviral signaling after therapy.
- Basal keratinocytes showed decreased cytokine signaling and reduced communication with NK cells following treatment.
- CCL19+ fibroblasts were prominent in untreated LPP but attenuated with therapy, alongside downregulated interferon signaling.
- TYK2 inhibition with deucravacitinib suppresses inflammatory circuits in LPP, indicating a promising therapeutic strategy.